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Abstract
Background: Diabetes prevalence is increasing. The Finnish Diabetes Prevention Study (DPS)
showed a 58% reduction in Type 2 Diabetes (T2D) incidence in adults with impaired glucose
tolerance (IGT). The European Diabetes Prevention Study (EDIPS) extends the DPS to different
European populations, using the same study design. In the Newcastle arm of this study (EDIPS-
Newcastle), we tested the hypothesis that T2D can be prevented by lifestyle intervention and
explored secondary outcomes in relation to diabetes incidence.
Methods: We recruited 102 participants (42 men and 60 women, mean age 57 years, mean BMI
34 kgm-2) with IGT to EDIPS-Newcastle and randomised to Intervention and usual care Control
groups. The intervention included individual motivational interviewing aimed at: weight reduction,
increase in physical activity, fibre and carbohydrate intake and reduction of fat intake (secondary
outcomes). The primary outcome was diagnosis of T2D.
Results: Mean duration of follow-up was 3.1 years. T2D was diagnosed in 16 participants (I = 5, C
= 11). Absolute incidence of T2D was 32.7 per 1000 person-years in the Intervention-group and
67.1 per 1000 person-years in the Control-group. The overall incidence of diabetes was reduced
by 55% in the Intervention-group, compared with the Control-group: RR 0.45 (95%CI 0.2 to 1.2).
Explanatory survival analysis of secondary outcomes showed that those who sustained beneficial
changes for two or more years reduced their risk of developing T2D.
Conclusion: Our results are consistent with other diabetes prevention trials. This study was
designed as part of a larger study and although the sample size limits statistical significance, the
results contribute to the evidence that T2D can be prevented by lifestyle changes in adults with
IGT. In explanatory analysis small sustained beneficial changes in weight, physical activity or dietary
factors were associated with reduction in T2D incidence.
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Background
The prevalence of type 2 diabetes (T2D) is increasing rap-
idly and there are causal associations with obesity, diet
and physical inactivity[1]. In the UK almost 5% of people
have T2D and treatment costs absorb a high proportion of
the health care budget[2]. Type 2 diabetes affects both
quality of life and mortality and is a growing public health
challenge.
Type 2 diabetes is a progressive metabolic disease with
impaired glucose tolerance (IGT) as an early stage in dis-
ease development [3]. Several large, well-designed trials
with long-term follow-up, evaluating interventions to pre-
vent the onset of diabetes in people with IGT have been
published [4-8]. The Finnish Diabetes Prevention Study
(DPS) showed a 58% reduction in T2D incidence follow-
ing lifestyle intervention in adults with IGT[8]. The Euro-
pean Diabetes Prevention Study (EDIPS) extends the DPS
to different European populations, using a similar study
design[9,10]. The other EDIPS centres, in addition to Fin-
land and Newcastle, are in Maastricht, the Netherlands
and Sardinia, Italy.
The EDIPS in Newcastle upon Tyne, UK (EDIPS-Newcas-
tle) was designed to contribute to the evidence for diabe-
tes prevention by lifestyle modification in people with
IGT. In this paper, we describe the methods and report
both pragmatic and explanatory analyses of EDIPS-New-
castle in relation to diabetes prevention.
Methods
Ethics statement
The Newcastle and North Tyneside NHS Research Ethics
Committee approved the study protocol and all partici-
pants gave informed, written consent before the start of
the study.
Study design, randomisation and end points
We conducted a Randomised Controlled Trial (RCT) with
one Intervention and one Control arm. Participants were
randomly allocated either to intensive behavioural inter-
ventions to promote dietary modification and increased
physical activity or to a minimal intervention Control
group. The planned maximum follow-up for any individ-
ual was five years.
Recruitment was by referral from primary care physicians
who identified eligible people likely to be at risk of
impaired glucose regulation (using the criteria: aged over
40 and overweight (BMI > 25 kgm-2)) from their primary
care databases and invited them to participate.
Oral glucose tolerance tests (OGTT) were conducted in
the Clinical Research Facility, Royal Victoria Infirmary
Newcastle upon Tyne. Eligible participants (with IGT)
were randomly allocated to the Intervention (I) or Con-
trol (C) group using randomisation lists, prepared inde-
pendently by the EDIPS co-ordinating centre in Helsinki.
Randomisation was stratified by sex and by two hour
plasma glucose value (derived from the mean of two
standard oral glucose tolerance tests (OGTTs) - stratum 1:
7.8 to 9.4 mmol/l; stratum 2: 9.5 to 11.1 mmol/l). Blind-
ing of participants and intervention staff was not possible.
Data collection staff were blinded to the extent that this
was possible given participants' knowledge of their alloca-
tion.
Outcomes
1. Development of T2D, diagnosed on the basis of two
OGTTs conducted with 1-12 weeks of each other, assessed
annually from baseline, was the primary study end point.
2. Other end points were myocardial infarction or sudden
cardiac death, intermittent claudication, stroke or death
from other causes.
3. Secondary outcomes were changes in BMI (kgm-2),
intakes of carbohydrate and fat (as percentages of total
energy intake) and dietary fibre (g), and participation in
physical activity (minutes of moderate aerobic physical
activity per day).
Inclusion and exclusion criteria
We included people aged over 40 years with BMI > 25
kgm-2 and with established IGT defined as a mean 2-hour
plasma glucose value ≥ 7.8 mmol/l and < 11.1 mmol/l
from two consecutive standard OGTTs (glucose load 75 g)
conducted between one and 12 weeks apart (World
Health Organisation 1999 classification)[11]. If the 2-h
OGTT value was just over the diabetes threshold (11.1-
11.5 mmol/l) or under the IGT threshold (7.3-7.7 mmol/
l), a second OGTT was performed within 1-12 weeks. If
the mean of the 2-h values from the two OGTTs was ≥ 7.8
and <11.1 mmol/l the individual was eligible for inclu-
sion. A diabetic value in the second OGTT was an exclu-
sion criterion, even if the mean value was in the IGT range.Page 2 of 14
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chronic illness that would make participation in moderate
physical activity impossible, or on a special diet for medi-
cal reasons were excluded.
Measurements
All participants received a clinical assessment prior to ran-
domisation and annually thereafter, including an OGTT,
anthropometric and blood biochemistry measurements.
Additionally they were asked to complete a health status
questionnaire (RAND-36),[12] the WHO cardiovascular
questionnaire[13] and annual three-day (two week days
and one weekend day) diet and physical activity diaries.
Assessments were conducted in the Clinical Research
Facility, Royal Victoria Infirmary in Newcastle upon Tyne.
Body weight was measured to the nearest 0.1 kg in light
indoor clothing using SECA 770 electronic scales (Alpha
Model 770, SECA Limited, Birmingham, UK). Height was
measured to the nearest half centimetre using a SECA 225
stadiometer (SECA Limited, Birmingham, UK). Waist cir-
cumference was measured to the nearest centimetre at the
midpoint between the iliac crest and the lower rib margin.
Percentage body fat was measured by bioelectrical imped-
ance, using a BODYSTAT 1500 (BODYSTAT Ltd, Douglas,
Isle of Man, UK).
Blood was collected from the antecubital vein with the
participant in a sitting position using a needle to insert a
cannula. If a tourniquet was used it was opened immedi-
ately after the needle had entered the vein. Glucose was
measured in venous plasma, using a Yellow Springs glu-
cose analyser (Yellow Springs Instrument co Inc, Ohio,
USA.). Food portion sizes were validated by the study die-
tician using a photographic food atlas [14] and nutrient
composition was analysed using Microdiet software
(Downlee Systems, Salford, UK). The activity diary cov-
ered the whole 24 hour period on all three days. Partici-
pants were asked to record activity for each 30 minute
period throughout the day starting from midnight (mid-
night to 00.30, 00.30 to 1.00, 1.00 to 1.30 etc.) using an
integer scoring system based on MET scores. For example,
lying down was scored 1 and brisk walking was scored 6.
A 24-hour activity score of 80 would be achieved by lying
down for eight hours and sitting for the rest of the day.
Thirty minutes of brisk walking would add four to a par-
ticipant's score on any day.
Interventions
Behavioural interventions consisted of regular individual
advice from a dietician and physiotherapist trained in
motivational interviewing [15]. Intervention participants
were also invited to some group sessions, notably 'cook
and eat' events. They also received a regular quarterly
newsletter. The newsletter contained: healthy eating reci-
pes, nutritional information, suggestions for local walks,
and exercise options. The dietary intervention provided
advice and counselling to develop an individual plan for
behaviour change, with the aim of achieving: >50% total
dietary energy intake from carbohydrate, reduced total
and saturated fat intake with <30% total dietary energy
from fat, increased fibre intake, and weight loss to achieve
BMI <25 kgm-2[16]. Analysis of participants' three day
food diaries, collected quarterly, and regular weight and
waist measurements were used to tailor individual dietary
advice. The physical activity intervention was designed to
encourage participation in increased physical activity
equivalent to accumulating 30 minutes of moderate aero-
bic physical activity per day. Analysis of participants' three
day activity diaries, collected quarterly, was used in moti-
vational feedback and to tailor goals for increasing physi-
cal activity, which were negotiated at each visit.
Participants in the Intervention group were seen by the
intervention team (dietician and physiotherapist) for
approximately 30 minutes per session, immediately fol-
lowing randomisation and two weeks later, then monthly
for the first three months and every three months thereaf-
ter up to five years. In addition to individual and group
activities, participants received an information pack
detailing facilities and opportunities for physical activity
in Newcastle upon Tyne, a City Card (a discount scheme
run by Newcastle Leisure Services offering up to 80% dis-
count on access to physical activity facilities) and the
opportunity to meet with a trainer at a local leisure centre
and take part in an induction session. Information gener-
ated from earlier studies in Newcastle was used to tailor
the intervention to the local conditions [17-19]
Control condition
Both Intervention and Control groups were offered stand-
ard health promotion advice including widely available
contemporary written leaflets on healthy eating and phys-
ical activity. Control group participants were otherwise
offered 'usual care' by their primary care physician.
Sample size
EDIPS-Newcastle was designed to contribute to the Euro-
pean study. We aimed for a sample size of 100 partici-
pants (50 in each arm), contributing to a planned total of
750 participants across Europe.
Analysis
The Statistical Package for Social Scientists (SPSS inc. ver-
sion 15) was used for analyses. We used independent t-
tests to compare continuous variables and Chi-squared
tests to compare categorical variables in the InterventionPage 3 of 14
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treat) analysis of the primary endpoint was conducted
using Kaplan-Meier survival analysis to determine the dif-
ference in relative risk of cumulative incidence of diabetes
between the Intervention and Control groups.
For secondary outcomes we used independent t-tests to
compare the Intervention and Control group means of
continuous variables at baseline and in each year of the
study.
For the explanatory analyses of secondary outcomes, we
pooled the Intervention and Control groups and consid-
ered each secondary outcome measure in turn. For these
outcomes we used a scoring system whereby any individ-
ual's beneficial change from their baseline value in an out-
come measure was scored 1 for each year of beneficial
change (cut off change values were 0.01 for beneficial
increase or -0.01 for beneficial reduction) and all other
values (no change or detrimental change) were scored 0.
The scores for each participant were totalled across study
years and the participants were divided into two groups
(for each measure separately): a 'sustained change' group
with a score of two or more, indicating beneficial change
in the parameter for at least two years; and a 'no sustained
change' group with a score less than 2, indicating less than
two years beneficial change, no change or detrimental
change. These groups were then compared using Kaplan-
Meier survival analysis for progression to T2D. We also
used independent t-tests to compare the 'sustained
change' and 'no sustained change' group means and the
difference between the groups for each of the secondary
outcomes at baseline and in each year of the study. Two
years of sustained change was chosen as the criterion for
explanatory analysis groups after consideration of other
possibilities (e.g. one year or three years) and with refer-
ence to the findings of our qualitative study linked to this
trial[20].
The baseline characteristics, weight, height, BMI, waist cir-
cumference, hip circumference, body fat %, plasma glu-
cose (fasting, 30 minute, 60 minute and 120 minute),
plasma insulin (fasting, 30 minute and 120 minute), age,
sex, socioeconomic status and working capacity of the
'sustained change' and 'no sustained change' groups for
each secondary outcome were compared for equality with
t-tests or Chi-squared tests as appropriate.
Results
Recruitment
We recruited 102 participants to the study and they were
randomised in equal numbers to the Intervention and
Control groups. Recruitment and trial progression are
shown in Figures 1 and 2.
Progression and trial profile
In the first year 19 participants (I = 11, C = 8) left the
study. The mean age of those who left in the first year was
54.8(95% CI: 49.3 to 60.4) years compared with 57.2
years (95% CI: 55.5 to 59.8) for those who stayed in the
study.
Comparison of Intervention and Control groups at 
baseline
There was little difference in any of the anthropometric,
clinical, social or demographic characteristics of the two
groups measured at baseline (Tables 1 and 2). Participants
were taking a range of drugs, including statins, beta block-
ers, anti-inflammatory medication and ACE inhibitors.
There were no significant differences in medication
between Intervention and Control groups.
Main outcomes
Mean duration of follow up was 3.11 years (range 0 to 5).
T2D was diagnosed in a total of 16 participants (I = 5, C =
11). The absolute incidence of T2D was 32.7 (95% CI:
10.7 to 74.6) per 1000 person years of follow-up in the
Intervention group and 67.1 (95% CI: 34.2 to 117.5) per
1000 person years of follow-up in the Control group. The
relative risk of T2D in the Intervention group, compared
with the Control group was 0.45 (95% CI: 0.2 to 1.2).
After year two of follow-up, there were no further inci-
dences of T2D in the Intervention group. Thus, overall the
cumulative incidence of diabetes was 55% less in the
Intervention group compared with the Control group.
Kaplan-Maier Survival analysis for Intervention and Con-
trol groups is shown in Figure 3.
A post study power calculation showed that 51 per group
provided 37% power to detect the difference found (80%
power would have required149 per group, a number that
will be exceeded in pooled analyses with other EDIPS cen-
tres).
If participants who left the trial and were later reported to
have developed T2D by their physician were included in
the analysis as having developed diabetes (rather than
having left), then the number of cases of diabetes
becomes 20 (I = 7, C = 13) and the relative risk of diabetes
incidence becomes 0.54 (95% CI:0.2 to 1.2).
Secondary outcomes
There were no significant differences in mean values for
secondary outcome measures between the Intervention
and Control groups at baseline or at annual follow-up in
any year. Analysis of difference from baseline value in
these secondary outcome measures showed a significant
difference between Intervention and Control groups in
weight loss at year 1 follow-up only (mean weight change:Page 4 of 14
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Flow of participants during recruitment to EDIPS-Newcastleigure 1
Flow of participants during recruitment to EDIPS-Newcastle.
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Flow of participants through EDIPS-Newcastle RCTigure 2
Flow of participants through EDIPS-Newcastle RCT. m participants who missed an annual review, but returned the fol-
lowing year (counted in for the survival analysis). r participants returning after missing an annual review  Reasons for leaving the 
trial:  a lack of time=4, physician diagnosis=1, illness=3 (1 of these died of colon cancer a year later)  b lack of time=5, changed 
mind=2, physician diagnosis=1, not known=2, died=1 c not known=2, mother died=1  d not known=1, family bereavement=1 
enot known=1 flack of time=1, not known=1, illness=1, back surgery=1 g lack of time=1, illness=1h lack of time=1i lack of 
time=1j 1= completed to year 5 and died later of lung cancer  
BMC Public Health 2009, 9:342 http://www.biomedcentral.com/1471-2458/9/342Intervention group = -2.3 kg, Control group = 0.01 kg;
mean difference -2.5 (95% CI: -4.2 to 0.7)kg, p = 0.007).
Only three participants achieved BMI < 25 kgm-2.
Post-hoc analysis of reversion to normal glucose tolerance
showed no difference between the intervention and the
control groups either for reversion to normal glucose tol-
erance on at least one occasion (I = 23, C = 22: RR 1.1
95%CI 0.7 to 1.6), or for reversion to normal glucose tol-
erance on two consecutive occasions (I = 17, C = 11: RR
1.5 95% CI 0.8 to 3.0).
Explanatory analysis of secondary outcomes
The results of the explanatory survival analyses are shown
in Tables 3 and 4 and Figures 4 and 5.
There was no significant difference at baseline between
the 'sustained change' and 'no sustained change' groups
defined by any of the secondary outcomes for the charac-
teristics compared.
Explanatory survival analysis of secondary outcome meas-
ures showed that, irrespective of randomisation alloca-
tion, groups of individuals who sustained beneficial
direction of change in secondary outcomes for two or
more years reduced significantly their risk of developing
T2D compared with others in the study. Kaplan-Meier Log
Rank, Chi-Square results: weight 16.6 (p < 0.001), physi-
cal activity 12.0 (p = 0.001), percentage carbohydrate
intake 7.4 (p = 0.007), percentage fat intake 11.5 (p =
0.001), or total fibre intake 4.2 (p = 0.041) (Figure 4).
There were almost equal contributions from the interven-
tion and control allocations to each 'sustained change'
group of individuals (Table 3)
The mean values for secondary outcomes were signifi-
cantly different at baseline for 'sustained beneficial
change' and 'no sustained beneficial change' groups in
each of the secondary outcome measures except body
weight. In each case the 'sustained change' group had a
Table 1: Baseline characteristics: mean (SD) for continuous variables by trial group.
Measurement Intervention (n = 51) Control (n = 51)
BMI (kgm-2) 34.1 (5.5) 33.5 (4.6)
Waist (cm) 104.6 (11.3) 104.3 (9.2)
Hip (cm) 111.0 (11.7) 110.3 (9.0)
Weight (kg) 93.4 (16.0) 90.6 (12.5)
Height (cm) 165.5 (8.9) 164.9 (10.2)
Body fat % 40.2*(9.4) 40.1 (9.9)
Plasma glucose (mmol/l)
Fasting 5.7 (0.6) 5.8 (0.5)
30 minute 9.9 (1.3) 9.8*(0.9)
60 minute 11.5 (1.9) 11.5*(1.6)
120 minute 8.7 (1.1) 8.9 (1.3)
Plasma insulin (mU/l)
Fasting 16.9 (12.4) 17.3 (7.4)
30 minute 97.5 (47.1) 85.08 (40.4)
120 minute 118.0 (58.0) 122.18 (55.3)
*n = 49
Table 2: Baseline characteristics: number (%) by trial group for demographic variables.
Intervention (n = 51) Control (n = 51)
Age [mean (range)] 56.8 (40-72) 57.4 (38-74)
Sex
Male 21 (41.2) 20 (39.2)
Female 30 (58.8) 31 (60.8)
Current working capacity
Retired 24 (47.1) 23 (54.8)
Full working capacity 18 (35.3) 17 (40.5)
Unable to work 6 (11.8) 0
Data unavailable 3 (5.9) 2 (4.8)
Socio-economic status by type of work
Manual 23 (45.1) 26 (51.0)
Non-manual 19 (37.3) 19 (37.3)
Data unavailable 9 (17.6) 6 (11.8)Page 7 of 14
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sustained change group had significantly more beneficial
values for percentage energy intake from fat from year 2
onwards and for fibre intake from year 1 onwards. The
distribution of change, based on mean annual values, in
the sustained change and no sustained change groups for
each secondary outcome measure are shown in Figure 5
and Table 5.
Discussion
Summary of main findings
The results of the EDIPS-Newcastle suggest that progres-
sion to T2D can be prevented or delayed by interventions
designed to change the lifestyles of participants with IGT.
The overall incidence of diabetes was reduced by 55% in
the Intervention group compared with the Control group,
a magnitude of effect similar to that seen in the other
main diabetes prevention trials [4-8]. However this study
was designed as part of a larger study and was not pow-
ered for statistical significance.
Explanatory analysis highlights the efficacy of weight loss
and of maintaining beneficial changes in diet and physi-
cal activity. The baseline differences in diet and physical
activity measures suggest that those with the greatest
capacity for beneficial change at baseline (because they
were furthest from the healthy targets) were most able to
sustain and to benefit from the changes made. The annual
changes (means and distributions) in the groups that did
and did not sustain beneficial change, demonstrate that
small amounts of sustained change are effective in reduc-
ing risk.
Strengths and limitations
Our study built on the highly successful Finnish DPS, rep-
licating its methods closely. Participants were recruited
following two consecutive OGTTs taken between one and
12 weeks apart, providing strong evidence of IGT at base-
line. The interventions were adapted for the UK cultural
context, but we retained the same intervention targets for
participants. A major strength was the length of follow-up
(mean 3.1 years), equivalent to that achieved in the other
main diabetes prevention trials [4-8].
As with any pragmatic trial, there were some limitations.
EDIPS-Newcastle was planned as part of a larger study and
was not powered to measure significant changes in inci-
dence of T2D or secondary outcomes. Nevertheless, the
results accord with previous trials and add to the existing
evidence that progression to T2D can be prevented or
delayed by lifestyle changes. Data will be pooled with
those from other EDIPS collaborating centres for substan-
tive analyses. Recruitment took longer than expected (18
months instead of 6 months), which meant that, despite
an extension to the study period, we were unable to fol-
low-up 15 cases at five years. Some of the problems in
recruiting and maintaining the study sample are high-
lighted in Figures 1 and 2. Of the 141 people who received
a second OGTT, 26 (18%) were found to have reverted to
NGT, more people than anticipated left the study early,
especially in the first year for various reasons, and some
participants failed to complete the baseline data collec-
tion.
In the explanatory analyses, we compared individual
change in secondary outcomes with each participant's
own baseline data. This had the advantages both of meas-
uring the direction of individual change, which we classi-
fied as beneficial or not irrespective of whether the
participant had achieved the intervention target (e.g.
>50% energy intake from carbohydrate), and taking
account of individual variations in reporting (e.g. of die-
tary intake).
Meaning and implications of the findings
Our findings for the primary outcome concur well with
previous trials and indicate >50% reduction in risk of
development of T2D is achievable in those with IGT when
randomised to a lifestyle intervention [4-8]. In addition
the results presented here, together with an associated
qualitative study, [20] led us to investigate the effects of
sustained beneficial behavioural change among some
members of the Control group (in addition to partici-
pants in the Intervention group) and to determine the
importance of maintaining change in the prevention of
T2D. The explanatory analysis demonstrated the efficacy
Progression to type 2 diabetes by trial groupFigu  3
Progression to type 2 diabetes by trial group.Page 8 of 14
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as individual beneficial change.
Whilst the control treatment was 'minimal intervention',
it involved an annual clinical review and annual food
intake and physical activity diaries. It has been recognised
that a diagnosis of IGT, together with annual clinical
reviews, constitute rather more than 'usual care'[21]. The
motivational effect of monitoring needs to be assessed
separately and considered in future pragmatic trials.
The problem of identifying persistent IGT for trial recruit-
ment has been partly addressed since we commenced this
trial by the development of prospective diabetes risk
scores, such as FINDRISC [22]. Risk scores could also
reduce the potential for selection bias when participants
are recruited through primary care. Large trials, where the
participants have been recruited on the basis of risk scores,
are underway [23]. However risk scores do not diagnose
T2D nor monitor progression, so the OGTT is likely to
remain the diagnostic test of choice in future trials.
Different people require different motivational input to
achieve behavioural change: for some, risk identification
at baseline is decisive; others need continual support to
change behaviour. In the Intervention group, engagement
with the intervention varied from those participants who
remained in the trial but returned only for the clinical
reviews and those who attended all opportunities. In
addition we were aware that some Control group partici-
pants sought help from elsewhere (e.g. weight loss
groups). Future research should identify sub-groups with
different levels of motivation for targeting with more or
less intensive interventions.
Compared with the Finnish DPS, EDIPS-Newcastle had a
larger proportion of participants who left the trial in the
first year. In Finland much primary health care, including
health promotion, is delivered via occupational health.
This is not the case in the UK [24]. Some of our partici-
pants took a day from their employment annual leave
allowance to attend their clinical review. Finding ways of
improving the accessibility of intervention opportunities
is an important area for further research.
Future pragmatic trials of the efficacy of lifestyle interven-
tion in T2D prevention should address: achieving higher
levels of recruitment; acceptable, ethical and efficient data
collection tools; and acceptable, safe and efficient moni-
toring schemes to evaluate trial progression. This may
Table 3: Relationship between sustained change* in secondary outcomes and progression to T2D by trial group.
Number in intervention 
group (%)
Number in control 
group (%)
Total number (%) Number of cases of T2D 
over five years follow-up
Body weight
Sustained beneficial change 23 (45) 24 (47) 47 (46) 3
No sustained beneficial 
change
28 (55) 27 (53) 55 (54) 13
Physical activity score
Sustained beneficial change 18 (35) 19 (37) 37 (36) 2
No sustained beneficial 
change
33 (65) 32 (63) 65 (64) 14
Intake of dietary fibre
Sustained beneficial change 15 (29) 15 (29) 30 (29) 3
No sustained beneficial 
change
36 (71) 36 (71) 72 (71) 13
% energy intake from fat
Sustained beneficial change 21 (41) 21 (41) 42 (41) 3
No sustained beneficial 
change
30 (59) 30 (59) 60 (59) 13
% energy intake from 
carbohydrate
Sustained beneficial change 15 (29) 16 (31) 31 (30) 2
No sustained beneficial 
change
36 (71) 35 (69) 71 (70) 14
* Sustained beneficial change in secondary outcome measures was defined as: a beneficial change (>0.01 units) maintained for two or more years 
(i.e. weight loss, reduction in % energy intake from fat, increase in % intake from carbohydrate, increase in intake of dietary fibre and increase in 
physical activity score).Page 9 of 14
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tions for intervention delivery, including workplaces.
Refining the physical activity and dietary advice within
T2D prevention interventions to maximise initiation,
magnitude and maintenance of change remains a contin-
uing challenge and should be the subject of further inves-
tigation.
Diabetes prevention policies and management pro-
grammes are currently being implemented in some Euro-
pean countries, notably in Finland and Germany, and
European guidelines for the primary prevention of T2D
are being developed[25,26]
EDIPS-Newcastle was planned as part of a larger study.
Subsequent analysis of data from the combined European
study centres will further illuminate diabetes prevention.
Conclusion
In conclusion: the results of the Newcastle arm of the
European Diabetes Prevention Study are consistent with
those of other diabetes prevention trials. This study was
designed as part of a larger study and although the sample
size limits statistical significance, the results contribute to
the evidence that T2D can be prevented by lifestyle
changes in adults with IGT. In explanatory analysis we
showed that small sustained beneficial changes in second-
Table 4: Mean (SD) values of secondary outcomes: comparison of sustained beneficial change* and no sustained beneficial change 
groups in each study year.
Outcome Time Sustained beneficial change No sustained beneficial 
change
Difference p-value
n Mean (SD) n Mean (SD) Mean (95% CI)
Weight (Kg)
Year 0 47 91.4 (12.8) 55 92.6 (15.6) -1.2 (-6.9, 4.5) 0.68
Year 1 47 88.4 (14.7) 35 93.0 (13.8) -4.6 (-10.8, 1.6) 0.15
Year 2 47 87.0 (13.7) 25 93.5 (17.0) -6.5 (-13.8, 0.9) 0.08
Year 3 43 86.7 (13.4) 17 87.4 (9.2) -0.7 (-7.8, 6.4) 0.84
Year 4 43 87.9 (13.7) 13 88.0 (10.1) -0.1 (-8.3, 8.2) 0.99
Year 5 32 88.4 (14.2) 10 85.1 (11.7) 3.3 (-6.8, 13.3) 0.52
Activity(score/day)
Year 0 37 93.6 (8.3) 49 103.1 (16.7) -9.5 (-15.4,-3.5) 0.002
Year 1 33 101.0 (12.8) 26 100.9 (14.0) 0.1 (-6.9, 7.07) 0.99
Year 2 31 102.5 (12.4) 18 96.6 (14.1) 6.0 (-1.8, 13.8) 0.13
Year 3 33 106.4 (17.0) 18 100.6 (11.2) 5.8 (-3.1, 14.7) 0.20
Year 4 34 105.3 (11.6) 13 97.9 (12.6) 7.5 (-0.3, 15.2) 0.06
Year 5 22 103.7 (15.5) 10 103.2 (11.5) 0.4 (-10.8, 11.7) 0.94
Fibre (g/day)
Year 0 30 17.6 (6.1) 54 20.5 (6.5) -2.9 (-5.8, -0.0) 0.050
Year 1 29 22.4 (10.2) 37 16.2 (6.3) 6.2 (2.2, 10.3) 0.003
Year 2 27 24.4 (10.0) 32 17.8 (6.8) 6.6 (2.2, 11.0) 0.004
Year 3 27 21.2 (8.1) 26 15.7 (5.3) 5.5 (1.7, 9.3) 0.005
Year 4 24 21.5 (7.9) 22 16.7 (7.4) 4.7 (0.2, 9.3) 0.043
Year 5 20 20.6 (8.2) 13 15.1 (4.9) 5.4 (0.3, 10.6) 0.039
Fat (% energy)
Year 0 42 37 (07) 51 31 (09) 6.2 (2.6, 9.7) 0.001
Year 1 39 31 (10) 27 34 (06) -2.2 (6.5, 2.1) 0.306
Year 2 37 31 (06) 22 35 (06) -4.4 (7.8, -1.0) 0.011
Year 3 41 29 (07) 12 36 (07) -6.2 (-1.1, -1.7) 0.007
Year 4 36 29 (06) 10 35 (06) -5.2 (-9.5, -0.9) 0.02
Year 5 24 30 (07) 9 38 (05) -8.3 (-13.5, -3.1) 0.003
Carbohydrate (% energy)
Year 0 31 44(07) 52 49(08) -4.5(-8.1,1.0) 0.013
Year 1 28 48(11) 38 48(10) -0.3(-5.4,4.6) 0.89
Year 2 26 50(07) 33 46(10) 3.3(-1.2, 7.9) 0.15
Year 3 31 52(08) 22 44(11) 8.4(3.1, 13.7) 0.002
Year 4 28 51(10) 18 47(08) 3.5(-2.1, 9.1) 0.22
Year 5 21 48(09) 12 47(07) 1.0(-5.2, 7.2) 0.74
* Sustained beneficial change in secondary outcome measures was defined as: a beneficial change (>0.01 units) maintained for two or more years 
(i.e. weight loss, reduction in % energy intake from fat, increase in % intake from carbohydrate, increase in intake of dietary fibre and increase in 
physical activity score).Page 10 of 14
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Relationship between changes in secondary outcomes and progression to T2D in trial participants (trial groups pooled)Figure 4
Relationship between changes in secondary outcomes and progression to T2D in trial participants (trial groups 
pooled). This figure shows the results of survival analysis based on beneficial change in secondary outcome measures main-
tained for two or more years. Intervention and control group data was pooled for this analysis.
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Mean annual changes in secondary outcome measures by sustained beneficial change (A) and no sustained beneficial change (B) groupsFig re 5
Mean annual changes in secondary outcome measures by sustained beneficial change (A) and no sustained 
beneficial change (B) groups. This figure shows the range and distribution of change in secondary outcome measures in the 
two groups defined by A: 'beneficial direction of change in an outcome measure sustained for two or more years' and B: no 
beneficial direction of change in the outcome measure. Intervention and control group data was pooled for this analysis.
BMC Public Health 2009, 9:342 http://www.biomedcentral.com/1471-2458/9/342ary outcome measures: weight loss, increase in physical
activity, reduction in dietary energy intake, reduction in
percentage fat intake and increase in percentage fibre
intake, were associated with reduction in T2D incidence.
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